PHS
PBYI icon

PFM Health Sciences’s Puma Biotechnology PBYI Stock Holding History

PFM Health Sciences’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,689,538
Closed -$39.7M – 72
2019
Q3 		$39.7M Buy
3,689,538
+851,162
+30% +$9.19M 1.17% 33
2019
Q2 		$36.1M Buy
2,838,376
+234,456
+9% +$5.4M 0.69% 48
2019
Q1 		$101M Buy
+2,603,920
New +$79.5M 2.23% 10
2018
Q4 		– Sell
-1,851,638
Closed -$84.9M – 118
2018
Q3 		$84.9M Buy
1,851,638
+254,855
+16% +$12.3M 1.24% 29
2018
Q2 		$94.5M Sell
1,596,783
-435,836
-21% -$25.3M 1.48% 16
2018
Q1 		$138M Buy
2,032,619
+210,819
+12% +$15.8M 2.81% 7
2017
Q4 		$180M Buy
1,821,800
+452,221
+33% +$50.6M 4.27% 2
2017
Q3 		$164M Sell
1,369,579
-312,579
-19% -$29.1M 3.22% 5
2017
Q2 		$147M Buy
1,682,158
+616,802
+58% +$34.5M 3.96% 3
2017
Q1 		$39.6M Sell
1,065,356
-78,332
-7% -$2.86M 0.99% 43
2016
Q4 		$35.1M Buy
+1,143,688
New +$49.5M 0.99% 35
2016
Q3 		– Sell
-1,471,879
Closed -$43.8M – 102
2016
Q2 		$43.8M Buy
+1,471,879
New +$46M 1.32% 35

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PFM Health Sciences's PBYI Position: Q4 2019 in Review

PFM Health Sciences sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 3,689,538 shares — an estimated $39.7M sold.

PFM Health Sciences first reported a position in PBYI in Q2 2016 and held it in 12 quarters. The position peaked at $180M in Q4 2017. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

  • PFM Health Sciences reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
  • PFM Health Sciences sold 3,689,538 Puma Biotechnology shares in Q4 2019, an estimated $39.7M.
  • PFM Health Sciences first reported a position in Puma Biotechnology in Q2 2016 and held it in 12 quarters.
  • PFM Health Sciences's Puma Biotechnology position peaked at $180M in Q4 2017.
  • 133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on PFM Health Sciences's 13F filing for Q4 2019, filed 14 Feb 2020.